Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Nyxoah ( (NYXH) ).
On January 21, 2026, Nyxoah SA announced a new investment to further expand its Belgian manufacturing capacity as it scales up to meet growing demand for its Genio obstructive sleep apnea therapy in the United States and international markets. In addition to its existing contract manufacturing in the U.S., the company will establish a nearly 2,000-square-meter facility with a state-of-the-art cleanroom at LégiaPark in the Liège region, developed in partnership with ABN Cleanroom Technology and supported by local investor Noshaq, a move aimed at improving gross margins, securing supply, and reinforcing Nyxoah’s integration into Belgium’s life sciences ecosystem while contributing to job creation and strengthening its global MedTech manufacturing footprint.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR11.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA is a Belgium-based medical technology company focused on developing and commercializing innovative neuromodulation solutions to treat obstructive sleep apnea (OSA), the most common sleep-disordered breathing condition associated with elevated mortality and cardiovascular risk. Its lead product, the Genio system, is a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy that has held a CE Mark since 2019 and received FDA approval in August 2025 for a subset of adults with moderate to severe OSA; the company is listed on Euronext Brussels and Nasdaq and targets both European and U.S. OSA markets, including patients with Complete Concentric Collapse, a group currently contraindicated for competing therapies.
Average Trading Volume: 69,252
Current Market Cap: €176.4M
For a thorough assessment of NYXH stock, go to TipRanks’ Stock Analysis page.